Stockscreener 앱 받기
65.49
4.62%
2.89
전일 마감가:
$62.60
열려 있는:
$64.09
하루 거래량:
9.64M
Relative Volume:
0.77
시가총액:
$11.01B
수익:
$803.32M
순이익/손실:
$-709.10M
주가수익비율:
-8.3958
EPS:
-7.8003
순현금흐름:
$-212.68M
1주 성능:
+6.71%
1개월 성능:
+60.28%
6개월 성능:
+24.98%
1년 성능:
+0.00%
1일 변동 폭
$61.63
$65.67
1주일 범위
$60.10
$71.97
52주 변동 폭
$22.89
$91.45
Tempus Ai Inc Stock (TEM) Company Profile
명칭
Tempus Ai Inc
전화
800-976-5448
주소
600 WEST CHICAGO AVENUE, CHICAGO
TEM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
65.49 | 10.62B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
VEEV
Veeva Systems Inc
|
242.78 | 38.63B | 2.75B | 714.14M | 1.09B | 4.33 |
|
HQY
Healthequity Inc
|
98.23 | 7.82B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
52.56 | 11.11B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
39.34 | 6.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | BTIG Research | Buy |
| 2025-02-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | 재개 | TD Cowen | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Outperform |
| 2024-12-09 | 개시 | Guggenheim | Buy |
| 2024-11-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-08-12 | 개시 | Piper Sandler | Neutral |
| 2024-07-09 | 개시 | BofA Securities | Buy |
| 2024-07-09 | 개시 | JP Morgan | Overweight |
| 2024-07-09 | 개시 | Longbow | Buy |
| 2024-07-09 | 개시 | Loop Capital | Buy |
| 2024-07-09 | 개시 | Morgan Stanley | Overweight |
| 2024-07-09 | 개시 | Needham | Buy |
| 2024-07-09 | 개시 | Stifel | Buy |
| 2024-07-09 | 개시 | TD Cowen | Buy |
| 2024-07-09 | 개시 | William Blair | Outperform |
모두보기
Tempus Ai Inc 주식(TEM)의 최신 뉴스
Tempus AI - The Pharma Letter
Pathos raises $365 million in funding round, touts $1.6 billion valuation - Crain's Chicago Business
Beyond The Numbers: 11 Analysts Discuss Tempus AI Stock - Benzinga
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order? - TradingView
Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs - Endpoints News
Boehringer and Tempus AI forge multi-year partnership - The Pharma Letter
Enterprise Development Unit Offloads Meta Platforms, Tempus AI Shares - marketscreener.com
Boehringer partners Tempus AI to enhance cancer therapy pipeline - Yahoo Finance
Tempus AI partners with Boehringer Ingelheim on cancer research By Investing.com - Investing.com South Africa
Tempus in pact with Boehringer Ingelheim for cancer drugs - Seeking Alpha
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline - BioSpace
Tempus AI enters collaboration to advance Boehringer Ingelheim’s cancer pipeline - TipRanks
Tempus AI partners with Boehringer Ingelheim on cancer research - Investing.com
Tempus AI Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily
Why Tempus AI Inc. (TEM) Skyrocketed On Tuesday - Insider Monkey
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025 - 01net
Tempus AI announces six posters accepted for presentation at ISPOR 2025 - TipRanks
Big Earnings Beats: 6 Stocks That Spiked After Reporting Results - 24/7 Wall St.
Tempus AI Reports Strong Growth and Strategic Partnerships in Earnings Call - MSN
Is Tempus AI, Inc. (TEM) the Best Performing Healthcare Stock to Buy Now? - Yahoo Finance
Tradr Launches First Leveraged ETF on Tempus AI - Yahoo Finance
Biovica Collaborates with Tempus to Expand the Commercial Reach of DiviTum(R) TKa - Yahoo Finance
Biovica collaborates with Tempus to expand the commercial reach of DiviTum® TKa - TradingView
11 Best Performing Healthcare Stocks to Buy Now - Insider Monkey
Why Tempus AI, Inc. (TEM) Skyrocketed On Wednesday - MSN
Jim Cramer Says Stay Away from This Nancy Pelosi Stock - MSN
These AI Stocks Posted Robust Results: Time to Buy? - The Globe and Mail
The Tempus AI, Inc. (NASDAQ:TEM) First-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Tempus AI Stock: Time to Double Down or Cut and Run? - MSN
Morgan Stanley raises Tempus AI price target to $65 from $60 - Investing.com Australia
Tempus AI COO Ryan Fukushima Sells 20,000 Shares - TradingView
Tempus AI, Inc. Class A (TEM) Gets a Hold from Piper Sandler - The Globe and Mail
Why These 10 Stocks Soared Today - Insider Monkey
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals - Benzinga
Tempus AI price target raised to $65 from $60 at BTIG - TipRanks
Global AI in Clinical Trials Market to Show Tremendous Growth at a CAGR of ~12% by 2032 | DelveInsight - GlobeNewswire Inc.
U.S. STOCKS ON THE MOVE-Bio-Techne, Johnson Controls, Tempus AI - TradingView
What’s Next For Tempus AI Stock? - Forbes
Tempus AI, Inc. (TEM): Among Most Popular Stocks on Robinhood in 2025 - Insider Monkey
Cathie Wood-Backed Tempus AI Says Pharma Contracts Solid Despite Biotech Funding Challenges, Tariff Pressures - Benzinga
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model - Benzinga
Tempus AI raises revenue guidance to $1.25B for 2025, supported by new $200M AstraZeneca deal - MSN
Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Tempus: Q1 Earnings Snapshot - MySA
Earnings call transcript: Tempus AI Q1 2025: Revenue Surges, Stock Dips - Investing.com India
Tempus AI Inc Reports Q1 2025 Revenue of $255.7 Million and Net Loss of $68 Million - GuruFocus
On heels of big data deals, Tempus AI touts robust revenue - Crain's Chicago Business
Tempus Ai Inc (TEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
10.08%
자본화:
|
볼륨(24시간):